Cervical Cancer Trial, Recruiting (NCT07009327)

Cervical Cancer Trial, Recruiting NCT07009327 Sponsor: Peking University Third Hospital Condition: Cervical Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07009327 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cervical Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People diagnosed with CIN3 (a high-grade abnormality of the cervix) who are being considered for photodynamic therapy (a light-based treatment)
People with a type 1 or type 2 transformation zone (a specific area of the cervix), where a colposcopy examination (a close-up examination of the cervix) is considered sufficient for assessment
People whose abnormal area on the cervix is fully visible during examination, with no edges hidden from view
People whose internal cervical canal cell sample (ECC) did not show any high-grade abnormal cells

Who may not be able to join:

People who have been diagnosed with, or are suspected of having, cervical cancer
People whose cervical cell test (TCT) has returned a result of HSIL (meaning significantly abnormal cells were found)
People whose abnormal cells involve the glands of the cervix
People who have a condition called Porphyria, or who may be allergic to red or blue light used in treatment
People who have serious or complex other health conditions alongside their cervical condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 7 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Qin Han, Peking Unniversity Third Hospital

Phone: 13810632686

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07009327

Sponsor: Peking University Third Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Cervical Cancer

Trial contact: 13810632686

More information: https://clinicaltrials.gov/study/NCT07009327

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People diagnosed with CIN3 (a high-grade abnormality of the cervix) who are being considered for photodynamic therapy (a light-based treatment)
People with a type 1 or type 2 transformation zone (a specific area of the cervix), where a colposcopy examination (a close-up examination of the cervix) is considered sufficient for assessment
People whose abnormal area on the cervix is fully visible during examination, with no edges hidden from view
People whose internal cervical canal cell sample (ECC) did not show any high-grade abnormal cells

Who may not be able to join:

People who have been diagnosed with, or are suspected of having, cervical cancer
People whose cervical cell test (TCT) has returned a result of HSIL (meaning significantly abnormal cells were found)
People whose abnormal cells involve the glands of the cervix
People who have a condition called Porphyria, or who may be allergic to red or blue light used in treatment
People who have serious or complex other health conditions alongside their cervical condition

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 7 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Peking University Third Hospital

Registry

ClinicalTrials.gov

Start date

1 January 2024

Est. completion

31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Efficacy of the treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov